Emergent BioSolutions Updates Revenue Guidance and Implements Cost-Cutting Measures
Emergent BioSolutions (EBS) has updated its full-year revenue guidance to a range of $600 million to $645 million following its third-quarter 2026 earnings call. The company is currently navigating competitive pressures within its commercial drug segment, specifically regarding NARCAN sales, which are seeing increased pricing pressure and market competition. To protect cash flow during this multi-year turnaround, the company implemented restructuring actions in August aimed at generating $40 million in annualized savings. Management is also focusing on diversifying revenue streams by expanding international medical countermeasure (MCM) sales, which reached more than 13 countries in the third quarter to reduce reliance on U.S. federal agency procurement cycles.
Tickers: $EBS
Topics: biopharmaceuticals cost cutting international expansion restructuring revenue guidance